For the first time in the program's history, Medicare is now covering prescription weight-loss drugs for eligible seniors, not just when those medications are prescribed for diabetes or heart disease, but specifically for obesity.
The Medicare GLP-1 Bridge, a pilot program announced and launched by the Centers for Medicare & Medicaid Services on July 1, 2026, gives qualifying Part D enrollees access to Wegovy, Zepbound KwikPen, or Foundayo for a fixed $50 monthly copay. The program runs through December 31, 2027, and is the clearest coverage expansion for GLP-1 obesity medications in Medicare's history.
